Analysis
PublicLEIDOS BIOMEDICAL RESEARCH, INC. holds $2.3B across 187 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 4 related awards under parent 75N91019D00024. Competition previously drew 2 offers. Recompete timing centers on the Sep 29, 2026 PoP end — agencies typically plan 12–18 months ahead.
Contract facts
FederalTHIS COVID TASK ORDER SUPPORTS NIAIDS NEED TO CONDUCT A TRIAL OF AN ADDITIONAL DOSE VACCINE TO EVALUATE VARIANT VACCINES ALONE OR IN COMBINATION IN AN IMMUNOLOGICALLY DIVERSE POPULATION. THE WORK INCLUDES THE ABILITY TO PROVIDE THE MANAGEMENT, OVERS
Recompete timing
PublicCurrent PoP ends Sep 29, 2026 (43 days remaining). Agencies typically plan 12–18 months ahead — at 1.4 months out, that window is already open. The buying decision is likely already in motion.
Watch this contract — one email →Incumbent footprint
Public recordLEIDOS BIOMEDICAL RESEARCH, INC. — $2.3B obligated across 187 awards (firm-wide, all agencies).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Track this contract
Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.
Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.
See all live recompete landscapes — who else is expiring, and where the openings are.
Open LEIDOS BIOMEDICAL RESEARCH, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.
Frequently asked questions
What is contract 75N91022F00007?
75N91022F00007 (THIS COVID TASK ORDER SUPPORTS NIAIDS NEED TO CONDUCT A TRIAL OF AN ADDITIONAL DOSE VACCINE TO EVALUATE VARIANT VACCINE…) is a Department of Health and Human Services (HHS) award with an estimated value of $38.1M, currently held by LEIDOS BIOMEDICAL RESEARCH, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.
Who is the incumbent on 75N91022F00007?
LEIDOS BIOMEDICAL RESEARCH, INC. is the incumbent with $2.3B across 187 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2026.
When does 75N91022F00007 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 29, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →